Michael is one of the foremost pioneers in CAR-T cell therapy, internationally renowned for his groundbreaking contributions to the design, development, and clinical translation of genetically engineered immune cells. As head of the Translational CAR-T Research Program at Universitätsklinikum Würzburg and coordinator of major European initiatives such as IMI T2EVOLVE and CAR FACTORY,he plays a central role in shaping the future of CAR-T therapies. His visionary leadership—spanning academia, clinical trials, and biotech innovation through T-CURX GmbH—has made him a driving force in bringing next-generation immunotherapies from the lab to the clinic.